Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Recruiting 1Active not recruiting 1

Sponsor Class

NIH 2

Study Type

Interventional 2

Sponsor

Cancer Type

Head & Neck 2Tumor-Agnostic 1

Conditions

Squamous Cell Carcinoma of Head and Neck 25Head and Neck Neoplasms 17Salivary Gland Neoplasms 5Oropharyngeal Neoplasms 4Nasopharyngeal Carcinoma 4Melanoma 4Carcinoma, Renal Cell 4Sarcoma 3Urinary Bladder Neoplasms 2Thyroid Neoplasms 2Recurrent Head and Neck Carcinoma 2Mouth Neoplasms 2Laryngeal Neoplasms 2Hypopharyngeal Neoplasms 2Carcinoma, Transitional Cell 2Carcinoma, Squamous Cell 2Carcinoma, Non-Small-Cell Lung 2Carcinoma 2Thyroid Carcinoma, Anaplastic 1Stomach Neoplasms 1Spinal Cord Compression 1Skin Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Neoplasms, Unknown Primary 1Neoplasms, Squamous Cell 1Neoplasms 1Neoplasm Metastasis 1Laryngeal Diseases 1Kidney Neoplasms 1

Interventions

Cisplatin 24pembrolizumab 23Magnetic Resonance Spectroscopy 19Specimen Handling 16Radiotherapy, Intensity-Modulated 12Carboplatin 12Cetuximab 111,2-diaminocyclohexaneplatinum II citrate 10Platinum 9Paclitaxel 9Radiotherapy 6Radiation 6Fluorouracil 6Biopsy 5Taxes 4Nivolumab 4Docetaxel 4(225)Ac-DOTA-c(RGDyK) 4X-Rays 3Pemetrexed 3Fluorodeoxyglucose F18 3reolysin 2pralsetinib 2ipatasertib 2cemiplimab 2atezolizumab 2Surgical Procedures, Operative 2Standard of Care 2Radiotherapy, Image-Guided 2Radiosurgery 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Carcinoma × Radiosurgery × Head & Neck × Clear all
NCT07156227 2026-06-03

Testing the Addition of an Anti-Cancer Drug, Camonsertib, to Radiation Therapy for Recurrent Head and Neck Squamous Cell Carcinoma

National Cancer Institute (NCI)

Phase 1 Recruiting
39 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT04576091 2024-12-13

Testing the Addition of an Anti-cancer Drug, BAY 1895344, With Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck Cancer

National Cancer Institute (NCI)

Phase 1 Active not recruiting
7 enrolled
Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms, Salivary Gland Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡